Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
出版年份 2023 全文链接
标题
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2023-06-07
DOI
10.1200/jco.22.02283
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
- (2022) Arnon P Kater et al. LANCET ONCOLOGY
- Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
- (2022) Sabina Kersting et al. Lancet Haematology
- Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia
- (2022) Paul M. Barr et al. Blood Advances
- Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
- (2021) Pin Lu et al. Blood Cancer Journal
- Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model for chronic lymphocytic leukemia
- (2021) Arnon P. Kater et al. Blood Advances
- High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial
- (2021) Moritz Fürstenau et al. BLOOD
- Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
- (2021) Othman Al-Sawaf et al. JOURNAL OF CLINICAL ONCOLOGY
- Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
- (2020) Marco Vincent Haselager et al. BLOOD
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2020) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
- (2020) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab‐related adverse events: A systematic review and meta‐analysis
- (2020) Irina Amitai et al. HEMATOLOGICAL ONCOLOGY
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
- (2019) Peter Hillmen et al. JOURNAL OF CLINICAL ONCOLOGY
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
- (2018) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition
- (2017) E Slinger et al. LEUKEMIA
- Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group
- (2016) Gabor Kovacs et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
- (2015) Ailin Guo et al. Oncotarget
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Defining the prognosis of early stage chronic lymphocytic leukaemia patients
- (2011) Chris Pepper et al. BRITISH JOURNAL OF HAEMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started